]i mobilization and TXA2 production via the inhibition of the COX-1 activity. Conclusions: These results strongly indicate that CAFA is a potent beneficial compound that elevates the level of cAMP-dependent protein phosphorylation in collagen-platelet interactions, which may result in the prevention of platelet aggregation-mediated thrombotic diseases.
Introduction
Platelet aggregation is essential for the formation of hemostatic plugs when normal blood vessels are known to have no inhibitory effects on TXA2 production 13) . It is known that CAFA inhibits the TXA2 production-associated enzyme COX-1 activity and the adhesion protein p-selectin expression in platelets 14) . On the other hand, both intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which function as antiplatelet regulators, decrease the level of [Ca 2＋ ]i. The antiplatelet effects of cAMP and cGMP are mediated by cAMPand cGMP-dependent protein kinases (A-kinase, G-kinase), which phosphorylate substrate proteins, IP3R and VASP [15] [16] [17] . IP3R phosphorylation involves in the inhibition of Ca 2＋ mobilization [18] [19] [20] , while VASP phosphorylation involves in the inhibition of VASP affinity for contractile protein filamentous actin to inhibit platelet aggregation 21, 22) . Therefore, inhibiting the mobilization of [Ca 2＋ ]i or increasing the level of cAMP and cGMP is very useful for evaluating the antiplatelet effects of substances or compounds. For instance, verapamil and theophylline elevate the cAMP level, and vasodilators (such as molsidomine and nitroprusside) and cGMP phosphodiesterase (PDE) inhibitors (such as zaprinast and erythro-9-[2-hydroxy-3-nonyl]adenine) elevate the cGMP level. These drugs are currently used to prevent and/or treat cardiovascular diseases as antiplatelet agents 23) . In terms of cyclic nucleotides, Chen et al. 24) reported that caffeic acid phenethyl ester, an analogue of CAFA, increases the level of cGMP only without affecting the level of cAMP in collagen-induced platelet aggregation. In the present study, in order to clarify and characterize the effects of aggregation-inducing molecules (i.e. Ca 2＋ , TXA2) and aggregation-inhibiting molecules (i.e. cAMP, cGMP) on the mode of CAFA-mediated antiplatelet action, we investigated the effects of CAFA on [Ca 2＋ ] mobilization, production of Ca 2＋ antagonistic molecules (cAMP, cGMP), downstream pathway (i.e. the phosphorylation of IP3R and VASP) of cAMP/ A-kinase and cGMP/G-kinase and TXA2 production and its associated COX-1 activity.
Materials and Methods

Materials
Collagen was obtained from the Chrono-Log Corporation (Havertown, PA., USA). cAMP-, cGMPand TXB2-enzymeimmunoassay (EIA) kits were purchased from GE Healthcare (Chalfont St, Giles, Buckinghamshire, UK). The COX-fluorescent activity assay kit was purchased from Cayman Chemical (Ann Arbor, MI., USA). The cytochrome C reductase (NADPH) assay kit, caffeic acid (CAFA), Fura 2-AM, protease inhibitor and other reagents were obtained endothelium and induces subsequent aggregation, secretion and procoagulant activity. Therefore, inhibiting platelet-collagen interactions is a promising approach for preventing thrombosis. An important role in the mechanism by which collagen induces platelet aggregation is played by thromboxane A2 (TXA2) formation 2) . It is known that collagen and its related peptide-induced stimulation of platelets activate tyrosine kinase-dependent mechanisms that involve in the tyrosine phosphorylation of Syk and phospholipase C-r2 (PLC-r2) via GPVI 3) . PLC-r2 phosphorylation hydrolyzes phosphatidylinositol 4, 5-bisphosphate (PIP2) to inositol 1, 4, 5-trisphosphate (IP3) and diacylglycerol (DG). Moreover, IP3 mobilizes cytosol free Ca 2＋ ([Ca 2＋ ]i) from the endoplasmic reticulum via IP3 receptor (IP3R). An increase in the level of [Ca 2＋ ]i activates both the Ca 2＋ /calmodulindependent phosphorylation of myosin light chain and the DG-dependent phosphorylation of cytosolic pleckstrin to induce platelet aggregation 4, 5) . In addition, DG is also hydrolyzed by DG-and monoacylglycerol-lipase to produce arachidonic acid (AA), a precursor of TXA2. The TXA2 production is associated with cyclooxygenase-1 (COX-1) and TXA2 synthase (TXAS), which convert AA to TXA2 6) . TXA2 interacts with the membrane receptor of other platelets in an autacoidal reaction that results in the elevation of [Ca 2＋ ]i via the Gq of the G-protein coupled receptor 2, 7, 8) . Therefore, the inhibition of COX-1 or TXAS is a useful indicator for monitoring the effects of TXA2 production on platelet-induced thrombosis. Antithrombotic drugs, such as aspirin and ozagrel, exert antithrombotic effects by inhibiting the generation of TXA2, which inhibits COX-1 and TXAS 9, 10) . A polyphenolic compound, (-)-epigallocatechin-3-gallate (EGCG), in green tea is known to produce cAMP via adenylate cyclase activation and subsequently phosphorylate vasodilator-stimulated phosphoprotein (VASP)-Ser 157 via A-kinase activation to inhibit [Ca 2＋ ]i mobilization and TXA2 production on collageninduced platelet aggregation 11) . The inhibition of TXA2 production by EGCG is involved in the inhibition of COX-1 12) . With regard to the effects of a phenolic compound, caffeic acid (CAFA, Fig. 1A ), anti-phosphor-IP3-receptor, anti-rabbit IgG-horseradish peroxidase conjugate (HRP) and lysis buffer were obtained from Cell Signaling (Beverly, MA., USA). Effects of collagen on rat platelet aggregation. Washed rat platelets (10 8 /mL) were stimulated with various of collagen (1 to 10 μg/mL) for 5 minutes in the presence of 2 mM of CaCl2 at 37 ℃. (C) Effects of CAFA pretreatment in the resting rat platelets. Washed rat platelets were preincubated with various concentrations of CAFA (10, 30 and 50 μM) in the presence of 2 mM of CaCl2 for 3 minutes at 37 ℃, then the platelet aggregation was measured for 5 minutes. (D) Effects of CAFA pretreatment on collagen-stimulated rat platelet aggregation. Washed rat platelets (10 8 /mL) were preincubated with various concentrations of CAFA (10, 30 and 50 μM) in the presence of 2 mM of CaCl2 for 3 minutes at 37 ℃, then stimulated with collagen (10 μg/mL) for 5 minutes. Platelet aggregation (%) was recorded as an increase in light transmission. Inhibition by CAFA was recorded as the percentage of the collagen-induced aggregation rate. The data are expressed as the mean±S.E.M. (n = 4). A B C D lagen (10 μg/mL) in an aggregometer (Chrono-Log, Corp., Havertown, PA., USA) at a constant stirring speed of 1,000 rpm. The reactions were terminated by the addition of ice-cold EDTA (5 mM) and indomethacin (0.2 mM). The amount of TXB2, a stable metabolite of TXA2, was determined with a Synergy HT Multi-Model Microplate Reader (Bio Teck Instrument, Winoosku, USA) using a TXB2 EIA kit. CAFA was dissolved in the suspension buffer.
Isolation of the Microsomal Fraction
To determine whether the suppression of TXA2 by CAFA (Fig. 2) was involved in the inhibition of COX-1 or TXAS, an enzyme source expressing COX-1 and TXAS proteins was required. Therefore, we separated the F1-and F2-cellular fractions from the platelet lysates. Washed rat platelets (10 8 platelets/ mL) containing platelet suspension buffer (pH 7.4) with 1% protease inhibitor (104 mM serine protease inhibitor [4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride], 80 mM serine protease inhibitor aprotinin, 4 mM aminopeptidase inhibitor bestatin, 1.4 mM cysteine protease inhibitor E-64 -[N-(transepoxysuccinyl)-L-leucine 4-guanidinobutylamide], 2 mM serine and cysteine proteases inhibitor leupeptin hemisulfate salt and 1.5 mM acid protease inhibitor pepstatin) were sonicated at a sensitivity of 100% for 20 seconds for one cycle, followed by 10 cycles on ice with a sonicator (Bandelin, HD2070, Germany) to obtain platelet lysates. The homogenates were centrifuged at 1,500 × g for 15 minutes, after which the supernatant was ultracentrifuged at 105,000 × g for 1 hour at 4 ℃ to obtain the microsomal fraction (F1-cellular fraction) containing the endoplasmic reticulum (ER) membrane 25) . The supernatant was termed the F2-cellular fraction. All of the separated fractions (homogenates and the F1-and F2-cellular fractions) were identified by cytochrome C reductase (a marker enzyme of the ER membrane) 26) and used as enzyme sources in Western blotting, as described below.
Cytochrome C Reductase Activity Assay
Cytochrome C reductase is a flavoprotein localized in the ER. The cytochrome C reductase activity of the fractions (homogenates and the F1-and F2-cellular fractions) was assayed using a cytochrome C reductase (NADPH) assay kit (Sigma Chemical Corp, St. Louis, MO., USA). The reaction was initiated by the addition of NADPH, and the reduction of cytochrome C was monitored according to the increase of absorbance at 550 nm for 7 minutes using a kinetic program.
Preparation of Washed Platelets
Blood was collected from Sprague-Dawley rats (6-7 weeks old, male) and anticoagulated with ACD solution (0.8% citric acid, 2.2% sodium citrate and 2.45% glucose). Platelet-rich plasma (PRP) was centrifuged at 125 × g for 10 minutes to remove the red blood cells, and the platelets were washed twice with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose and 1 mM EDTA, pH 6.9). The washed platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 0.49 mM MgCl2, 5.5 mM glucose and 0.25% gelatin, pH 7.4) to a final concentration of 5 × 10 8 /mL.
Human PRP anticoagulated with ACD solution was obtained from the Korean Red Cross Blood Center (Changwon, Korea). The PRP was centrifuged for 10 minutes at 125 × g to remove the red blood cells, and the platelets were washed twice with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose and 1 mM EDTA, pH 6.5). The washed human platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 0.49 mM MgCl2, 5.5 mM glucose and 0.25% gelatin, pH 6.9) to a final concentration of 5× 10 8 /mL. All of the above procedures were carried out at 25 ℃ to prevent platelet aggregation due to the effects of low temperature. The ethical committee for animal experiments of Inje University (Gimhae, Gyungnam, Korea) approved the animal experiments, and the Korea National Institute for Bioethics Policy Public Institutional Review Board (Seoul, Korea/ PIRB12-072-01) approved the human platelet experiments.
Measurement of Platelet Aggregation
Washed platelets (10 8 /mL) were preincubated for 3 minutes at 37 ℃ in the presence of 2 mM exogenous CaCl2 with or without CAFA and then stimulated with collagen (10 μg/mL) for 5 minutes. The aggregation was monitored using an aggregometer (ChronoLog, Corp., Havertown, PA., USA) at a constant stirring speed of 1,000 rpm. The aggregation rate was evaluated as an increase in light transmission. The suspension buffer was used as a reference. CAFA was dissolved in the suspension buffer.
Measurement of TXB2
Washed rat platelets (10 8 /mL) were preincubated with or without CAFA for 3 minutes in the presence of 2 mM CaCl2, and activated for 5 minutes with col-
Measurement of cAMP and cGMP
Washed rat platelets (10 8 /mL) were preincubated for 3 minutes at 37 ℃ with various concentrations of CAFA in the presence of 2 mM CaCl2 and then stimulated with collagen (10 μg/mL) for 5 minutes for platelet aggregation. The aggregation was terminated by the addition of 80% ice-cold ethanol. The levels of cAMP and cGMP were measured with the Synergy HT Multi-Model Microplate Reader (Bio Teck Instrument, Winoosku, USA) using cAMP and cGMP EIA kits. CAFA was dissolved in suspension buffer.
Determination of [Ca
2＋
]i PRP was incubated with 5 μM of Fura 2-AM at 37 ℃ for 60 minutes. Because Fura 2-AM is light sensitive, the tube containing the PRP was covered with aluminum foil during loading. The Fura 2-loaded washed rat platelets were prepared using the procedure described above, and 10 8 platelets/mL were preincubated for 3 minutes at 37 ℃ with or without CAFA, the A-kinase inhibitor Rp-8-Br-cAMPS and the G-kinase inhibitor Rp-8-Br-cGMPS in the presence of 2 mM CaCl2, then stimulated with collagen (10 μg/mL) for 5 minutes to evaluate [Ca 2＋ ]i. The Fura 2 fluorescence was measured using a spectrofluorometer (SFM 25; Bio-Teck Instrument, Italy) with an excitation wavelength that was changed every 0.5 seconds from 340 to 380 nm; the emission wavelength was set at 510 nm. The [Ca 2＋ ]i values were calculated using the method developed by Schaeffer 29) .
Western Blot Analysis of COX-1 and TXAS
Because COX-1 and TXAS are localized in the ER 27, 28) , we investigated which cellular fractions express COX-1 and/or TXAS. The protein concentrations in the separated fractions were measured using the Bradford method. The proteins of each fraction (30 μg) were separated on 8% SDS-PAGE. The separated proteins were electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane (GE Healthcare, NJ., USA). The immunoblot was prepared using primary antibodies (COX-1, 1:200, TXAS, 1:1000) and horseradish peroxidase conjugate secondary antibodies at a dilution of 1:10,000 (Santa Cruz Biotechnology Inc., CA., USA). Following treatment with the secondary antibodies (anti-mouse IgG-horseradish peroxidase conjugate (HRP) or anti-goat IgG-HRP), the detection of antibody-bound proteins in the membrane was performed using enhanced chemiluminescence (ECL) solution (GE Healthcare, Buckinghamshire, UK).
COX-1 Activity Assay
To measure the COX-1 activity, the F1-cellular fraction (20 μg protein) of rat platelets was preincubated with or without various concentrations of CAFA at 37 ℃ for 30 minutes. The COX-1 activity of the treated F1-cellular fraction was assayed using the COX-1 fluorescent assay kit (Cayman Chemical Co, Ann Arbor, MI., USA). /mL) were preincubated with CAFA for 3 minutes in the presence of 2 mM of CaCl2, then stimulated with collagen (10 μg/mL) in an aggregometer (Chrono-Log, Corp., Havertown, PA., USA). The level of TXA2 was determined with the content of TXB2 using the TXB2 EIA kit as described in "Materials and Methods." The data are expressed as the mean±S.E.M. (n = 4). ( Fig. 1B) 30) . Therefore, 10 μg/mL of collagen were used in this study. Since [Ca 2＋ ]i is a critical regulator of the platelet response, 2 mM of CaCl2 as an exogenous Ca 2＋ resource were used to examine the effects of CAFA (Fig. 1A) on collagen-induced platelet aggregation. The light transmission in response to various concentrations of CAFA (10, 30 and 50 μM) in intact platelets was 4.3±0.5% (at 10 μM of CAFA), 4.5± 0.6% (at 30 μM of CAFA) and 4.3±0.5% (at 50 μM of CAFA), respectively, which was not significantly different from that observed (4.5±0.6%) in the resting platelets (Fig. 1C) . This means that CAFA alone did not affect platelet aggregation compared with that observed in the intact platelets without CAFA. When the washed platelets were activated with 10 μg/mL of collagen in the presence of 2 mM of CaCl2, the aggregation rate was 81.2±2.5%. However, various concentrations of CAFA (10 to 50 μM) significantly reduced the collagen-stimulated platelet aggregation in a dose-dependent manner (Fig. 1D) .
Effects of CAFA on TXA2 Production
CAFA blocked the production of TXA2 (determined as TXB2) under collagen exposure (Fig. 2) . The TXA2 level in the intact platelets was 4.0±0.1 ng/10 8 platelets, which was increased markedly to 355.6±7.5 ng/10 8 platelets in the collagen-stimulated platelets (Fig. 2) . However, CAFA significantly reduced the production of TXB2 by 185.3±4.2 ng/10 8 platelets (47.9% inhibition at 50 μM) (Fig. 2) .
Effects of CAFA on the Microsomal COX-1 Activity
We measured which cellular fraction of the platelet lysates exhibits activity of cytochrome C reductase, an ER marker enzyme. As shown in Fig. 3A , we found that the F1-cellular fraction has the highest specific activity of cytochrome C reductase. Next, we determined which fraction from platelets expresses COX-1 and TXAS. Consequently, COX-1 (70 kDa) and TXAS (58 kDa) were strongly expressed in the F1-cellular fraction (Fig. 3B) . Because these results are in accordance with those showing that the F1-cellular fraction has the highest activity of cytochrome C reductase, it is thought that the F1-cellular fraction is a microsomal fraction. Because COX-1 in the F1-cellular fraction exhibits the highest activity of cytochrome C reductase compared with that of TXAS in the F1-cellular fraction, and it is known that the inhibition of collagen-induced platelet aggregation is resulted from the inhibition of COX-1 rather than TXAS 31) . In the present study, therefore, we used the F1-cellular fraction (microsomal fraction) to investigate the effects of CAFA on the COX-1 activity. As
Western Blot Analysis of IP3R and VASP Phosphorylation
Washed rat platelets (10 8 /mL) were preincubated with or without CAFA, the A-kinase inhibitor Rp-8-Br-cAMPS or the G-kinase inhibitor Rp-8-Br-cGMPS for IP3R phosphorylation and the A-kinase stimulator pCPT-cAMP or the G-kinase stimulator 8-Br-cGMP for VASP phosphorylation in the presence of 2 mM of CaCl2 for 3 minutes and then stimulated with collagen (10 μg/mL) for 5 minutes at 37℃ in an aggregometer (Chrono-Log, Corp., Havertown, PA., USA) at a constant stirring speed of 1,000 rpm. The reactions were terminated by adding an equal volume (250 μL) of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM serine/threonine phosphatase inhibitor β-glycerophosphate, 1 mM ATPase, alkaline and acid phosphatase, protein phosphotyrosine phosphatase inhibitor Na3VO4, 1 μg/mL serine and cysteine protease inhibitor leupeptin and 1 mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride, pH 7.5). Platelet lysates containing the same protein (20 μg) were used for the analysis. The protein concentrations were measured using a bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, USA). The effects of CAFA on VASP and IP3-receptor phosphorylation were analyzed using Western blotting. A 6-8% SDS-PAGE was used for electrophoresis and a PVDF membrane was used for protein transfer from the gel. The dilutions for anti-phosphor-VASP (Ser 157 ), anti-phosphor-VASP (Ser 239 ), anti-phosphor-IP3-receptor and anti-rabbit IgG-HRP were 1:1,000, 1:1,000, 1:1,000 and 1:10,000, respectively. The membranes were visualized using ECL. The blots were analyzed using Quantity One, Ver. 4.5 (Bio-Rad, Hercules, CA., USA).
Statistical Analysis
The experimental results are expressed as the mean±S.E.M. accompanied by the number of observations. The data were assessed using an analysis of variance (ANOVA). If the analysis indicated significant differences between the group means, then each group was compared according to the Newman-Keuls method. P＜0.05 was considered to be statistically significant.
Results
Effects of CAFA on Collagen-Induced Platelet Aggregation
The concentration of collagen-induced maximal platelet aggregation was approximately 10 μg/mL and collagen, CAFA (10 to 50 μM) significantly increased the cAMP level in a dose-dependent manner. CAFA (50 μM) increased the cAMP level by 7.1±0.12 pmoL/10 8 platelets in comparison with that observed in the resting platelets (3.8±0.10 pmoL/10 8 platelets) and the collagen-induced platelet aggregation (3.6±0.03 pmoL/10 8 platelets) (Fig. 4A) . When the platelets were incubated in the presence of both CAFA and collagen, CAFA (10 to 50 μM) significantly increased the cGMP level in a dose-dependent shown in Table 1 , the COX-1 activity in the absence of CAFA (control) was 52.5±2.5 pmoL/min/proteinmg. However, CAFA (50 μM) inhibited the COX-1 activity to 30.3±2.6 pmoL/min/protein-mg. The inhibitory degree of 50 μM of CAFA was 42.3% compared with that (52.5±2.5 pmoL/min/proteinmg) of the control. Accordingly, it is thought that CAFA involved in COX-1 inhibition in order to suppress the TXA2 production.
Effects of CAFA on cAMP and cGMP Production
We examined whether CAFA affected the production of cAMP and cGMP in the intact or collageninduced platelets. As shown in Fig. 4A and 4B , the cAMP level (3.6±0.03 pmoL/10 8 platelets) and cGMP level (1.1±0.01 pmoL/10 8 platelets) in the collagen-induced platelet aggregation were not significantly decreased compared with those (cAMP, 3.8± 0.10 pmoL/10 8 platelets; cGMP, 1.2±0.01 pmoL/10 8 platelets) observed in the intact platelets. With respect to collagen-induced platelet aggregation, the levels of cAMP and cGMP were weakly decreased compared with the basal levels in the intact platelets. When the platelets were incubated in the presence of both CAFA A B The F1-cellular fraction (20 μg of total protein) of rat platelets was preincubated with or without various concentrations of CAFA for 30 minutes at 37℃. The CAFA-induced COX-1 activity was assayed using the COX-1 fluorescent assay kit. Inhibition (%) = (intact cell− caffeic acid)/intact cell. The data are presented as the mean±S.E.M. (n=4). ＊ p＜0.05 compared with that of the CAFA-non-treated F1-cellular fraction of the platelets collagen-induced platelet aggregation; however, the increase was very weak (Fig. 5C ). As shown in Table 2 ]i mobilization (Fig. 5A) by CAFA results from cAMP/A-kinase-dependent IP3R phosphorylation by significantly increasing the cAMP level (Fig. 4A ), but not the cGMP level (Fig. 4B) . Therefore, we next determined whether CAFA affects IP3R phosphorylation in collagen-activated platelets.
Effects of CAFA on IP3 Receptor Phosphorylation
CAFA strongly phosphorylated IP3R (320kDa), and the ratio of phosphorylated IP3R to β-actin was increased in the presence of both CAFA and collagen (Fig. 6, lane 3 ) compared with that achieved (Fig. 6  lane 1, 2) by collagen only or that observed in the intact cells (control). In contrast, CAFA-elevated IP3R phosphorylation was completely inhibited by the A-kinase inhibitor Rp-8-Br-cAMPS (Fig. 6, lane 4) and only mildly inhibited by the G-kinase inhibitor Rp-8-Br-cGMPS (Fig. 6, lane 5) in the collagen-activated platelets.
Effects of CAFA on VASP Phosphorylation
We investigated whether CAFA-elevated cAMP and cGMP (Fig. 4A, B Effects of CAFA on cAMP production in the resting and collagen-stimulated rat platelets. (B) Effects of CAFA on cGMP production in the resting and collagen-stimulated rat platelets. Washed rat platelets (10 8 /mL) were preincubated with or without CAFA for 3 minutes in the presence of 2 mM of CaCl2 and then stimulated with collagen (10 μg/mL) for 5 minutes at 37 ℃. The reactions were terminated by adding 80% ice-cold ethanol. The cAMP and cGMP contents were measured using EIA kits. The data are expressed as the mean±S.E.M. (n = 4). A B gen only (Fig. 7A, lane 3, 4) . The cGMP-dependent phosphorylation of VASP (Ser 239 ) was not entirely caused by CAFA (Fig. 7B, lane 3) but was potently caused by the cGMP stimulator 8-Br-cGMP (Fig. 7B,  lane 4) .
Discussion
Collagen-induced rat platelet aggregation was inhibited by a low dose (10 to 50 μM) of CAFA (Fig. 1D) )] at 50kDa of VASP (Fig. 7A,  lane 2) , which involves in feedback inhibition by collagen 32) . The cAMP-dependent phosphorylation of VASP (Ser 157 )-50kDa in the presence of both collagen and CAFA was increased compared with that achieved by collagen only (Fig. 7A, lane 3) , and the A-kinase stimulator pCPT-cAMP, as a positive control, also phosphorylated VASP (Ser 157 )-50kDa (Fig. 7A, lane 4) . The ratio of p-VASP (Ser 157 )-50kDa to β-actin was increased by CAFA and the A-kinase stimulator pCPT-cAMP compared with that achieved by colla- (Fig. 8B) . This is a very high dose compared with that observed in the collageninduced rat platelet aggregation, which was inhibited to 60% by 50 μM of CAFA (Fig. 1D) . It has also been reported that a high value of IC50 (478.1±1.19 μM) of CAFA is required to inhibit collagen (1.0 μg/ mL)-induced human platelet aggregation in vitro 33) . Considering that the dose of collagen (10 μg/mL) used in our human experiment is 10-fold higher than that (1.0 μg/mL) used by Hubbard et al. 33) as an agoplatelet aggregation, CAFA could be clinically applied to the prevention of platelet aggregation-mediated thrombosis, which means that CAFA may inhibit the human platelet-collagen interaction in the first step of collagen adhesion to the subendothelium of injured blood vessels. Therefore, we investigated whether CAFA inhibits collagen-induced human platelet aggregation. As shown in Fig. 8 , CAFA inhibited collagen (10 μg/mL)-induced human platelet aggregation in a dose-dependent manner in vitro (Fig. 8A) , with an The increase (%) is calculated from Fig. 5A, B and C.   Fig. 6 . Effects of CAFA on the IP3R phosphorylation of resting or collagen-activated rat platelets. Lane 1, intact platelets (base); lane 2, collagen (10 μg/mL); lane 3, collagen (10 μg/mL)＋CAFA (50 μM); lane 4, collagen (10 μg/mL)＋CAFA (50 μM)＋ Rp-8-Br-cAMPS (100 μM); lane 5, collagen (10 μg/mL)＋CAFA (50 μM)＋Rp-8-Br-cGMPS (100 μM). Washed rat platelets (10 8 /mL) were preincubated with or without CAFA, the A-kinase inhibitor Rp-8-Br-cAMPS or the G-kinase inhibitor Rp-8-Br-cGMPS in the presence of 2 mM of CaCl2 for 3 minutes and then stimulated with collagen (10 μg/mL) for 5 minutes at 37 ℃ in an aggregometer. The reactions were terminated by adding an equal volume (250 μL) of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM serine/threonine phosphatase inhibitor β-glycerophosphate, 1 mM ATPase, alkaline and acid phosphatase, protein phosphotyrosine phosphatase inhibitor Na3VO4, 1 μg/mL serine and cysteine protease inhibitor leupeptin and 1 mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride, pH 7.5). The proteins were extracted, separated via SDS-PAGE, transferred to PVDF and immunoblotted with the indicated corresponding antibodies and anti-phosphor-IP3-receptor. the expression of both COX-1 and TXAS was observed in the F1-cellular fraction (Fig. 3B) , which means that the F1-cellular fraction corresponds to the microsomal fraction. In the present study, it is unknown whether protease inhibitors affect the cytochrome C reductase activity. Because the cytochrome C reductase activity is a relative activity in homogenates, the F1-cellular fraction and the F2-cellular fraction, even if protease inhibitors affect the cytochrome C reductase activity, it is thought that their relative activity is not significantly changed in homogenates, the F1-cellular fraction and the F2-cellular fraction because the order (F1-cellular fraction＞homogenates＞F2-cellular fraction) of strength in cytochrome C reductase is in accordance with that (F1-cellular fraction＞homoge-nates＞F2-cellular fraction) of the COX-1 expression (Fig. 3A, B) .
Accordingly, it is thought that the low cytochrome C reductase activity observed in the F2-cellular fraction (Fig. 3A) did not result from the degradanist to platelets, the value of IC50 (775 μM) of CAFA obtained in our human experiment is not significantly high compared with that (478.1±1.19 μM) obtained in another previous report 33) , because the degree of platelet aggregation is dependent on the dose of the agonist 34, 35) . However, there appears to be a dose difference between humans and rats with respect to the antiplatelet effects of CAFA.
The inhibition of collagen-induced platelet aggregation by CAFA (Fig. 1D) is associated with the inhibition of TXA2 production and Ca 2＋ mobilization. Because TXA2 production-associated enzymes (COX-1, TXAS) are localized in the ER, which also includes cytochrome C reductase, we assayed the activity of cytochrome C reductase and the expression of COX-1 or TXAS proteins to obtain the ER fraction from platelet lysates containing various kinds of protease inhibitors. The relative activity of cytochrome C reductase and the relative expression of COX-1 were highest in the F1-cellular fraction (Fig. 3A, B) . In particular, /mL) were preincubated with or without CAFA, the A-kinase stimulator pCPT-cAMP or the G-kinase stimulator 8-Br-cGMP in the presence of 2 mM of CaCl2 for 3 minutes and then stimulated with collagen (10 μg/mL) for 5 minutes at 37 ℃ in an aggregometer. The reactions were terminated by adding an equal volume (250 μL) of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM serine/threonine phosphatase inhibitor β-glycerophosphate, 1 mM ATPase, alkaline and acid phosphatase, protein phosphotyrosine phosphatase inhibitor Na3VO4, 1 μg/mL serine and cysteine protease inhibitor leupeptin and 1 mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride, pH 7.5). The proteins were extracted, separated via SDS-PAGE, transferred to PVDF and immunoblotted with the indicated corresponding antibodies and anti-phosphor-VASP (Ser 
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cGMP-stimulated phosphodiesterase (PDE2) hydrolyzing both cAMP and cGMP, cGMP-inhibited phosphodiesterase (PDE3) hydrolyzing cAMP rather than cGMP and cGMP-binding cGMP-specific phosphodiesterase (PDE5) hydrolyzing cGMP alone 18) . Although it is inferred that CAFA may involve in PDE2 inhibition to produce both cAMP and cGMP (Fig. 4A, B) in the present study, because we did not investigate the effects of CAFA on the activity of adenylate cyclase, PDE2, PDE3 and PDE5, we have no obvious evidence of how CAFA regulates the levels of cAMP and cGMP. Further investigation along these lines is underway.
CAFA-elevated cAMP and cGMP involved in the reduction of the level of Ca
2＋
, an aggregationinducing molecule, to inhibit platelet aggregation (Fig. 1D) . The downstream pathways of both cAMP/ A-kinase and cGMP/G-kinase involve in the phosphorylation of IP3R to inhibit [Ca 2＋ ]i mobilization [18] [19] [20] . Caffeic acid phenethyl ester (CAPE), an analogue of CAFA, is known to inhibit total [ 3 H]-inositol monophosphate production as an index of the IP3 production from PIP2 in collagen-activated platelets 41) , which indirectly shows that CAPE may inhibit IP3 production. In the present study, although it is unknown whether CAFA inhibits IP3 production as well as CAPE, and even if CAFA does not inhibit IP3 production in collagen-activated platelets, if CAFA stimulates IP3R phosphorylation in collagen-activated platelets, this is a clear evidence that CAFA inhibits [Ca 2＋ ]i tion of proteins, which is resulted from the absence of microsomes in the F2-cellular fraction. The inhibition of the collagen-elevated TXA2 level by CAFA (Fig. 2) was associated with the inhibition of the microsomal COX-1 activity ( Table 1) . In a previous study, we reported that chlorogenic acid (50 μM), an analogue of CAFA, inhibits the COX-1 activity in platelets to 69.7% compared with that observed (52.5±2.5 pmoL/ min/protein-mg) in the controls in vitro 36) . In addition, the COX-1 inhibitor aspirin (50 μM) inhibited the COX-1 activity in platelets to 11.3% compared with that observed (1.59 nmoL/min/protein-mg) in the controls in vitro 12) . An autacoidal molecule, TXA2, produces IP3 to mobilize [Ca 2＋ ]i via the G-protein coupled receptor/PLC-β pathway to constrict the vessel tract 7, 8, 35, [37] [38] [39] , which enforces thrombus formation. Therefore, CAFA may involve in antithrombotic effects by reducing collagen-elevated TXA2 production via the inhibition of COX-1.
In addition, the platelet-activating reagent-elevated TXA2 level is lowered by both cAMP and cGMP. This is associated with the activation of A-kinase or G-kinase, since these enzymes block Ca 2＋ mobilization by phosphorylating IP3R to inhibit the generation of the TXA2 substrate, AA 18, 40) . CAFA (50 μM) increased the cAMP level more so than the cGMP level in the collagen-induced platelet aggregation, a trend that is also observed with respect to phenolic compounds, such as EGCG 11) and chlorogenic acid 36) . The levels of cAMP and cGMP in platelets are regulated by A B lets) achieved by collagen only (Fig. 4B) 11) . If CAFA, which has an antiplatelet effect, is absorbed from the intestines to the blood vessels in vivo, this would be used to evaluate the clinical effects of CAFA. It is known that 95% of ingested CAFA is absorbed from the small intestine in humans 45) . In our other experiment, we observed that CAFA dose dependently inhibits collagen (10 μg/mL)-induced human platelet aggregation in vitro (Fig. 8A) , with an IC50 value of 775 μM (Fig. 8B) . If a subject consumes a 200-mL (7-oz) cup of coffee containing 35 mg (966 μM) to 175 mg (4.83 mM) of CAFA (MW. 180.16) 46, 47) , 918 μM to 4.59 mM of CAFA, corresponding to 95% of the ingested CAFA, would theoretically be absorbed from the small intestine to the blood vessels. The amount of absorbed CAFA (918 μM to 4.59 mM) would be enough to inhibit the platelet activity because the concentration is higher than the IC50 value (775 μM) of CAFA required to inhibit 50% of human platelet aggregation (Fig. 8B) . Accordingly, it is thought that the clinical antiplatelet effects of CAFA would be obtained by consuming CAFA content that is absorbable at an IC50 of least 775 μM of CAFA to inhibit the platelet activity. CAFA and its analogue chlorogenic acid are wildly distributed in coffee beverages, blueberries, apples and cider. In particular, because chlorogenic acid is hydrolyzed into CAFA in the human gastrointestinal tract 48) , coffee beverages, blueberries, apples and cider are very good sources of CAFA. In conclusion, the most important result of this study is that CAFA significantly decreased the levels of [Ca 2＋ ]i and TXA2, platelet-aggregating molecules. The inhibition of [Ca 2＋ ]i by CAFA resulted from IP3R phosphorylation via the upregulation of the Ca 2＋ -antagonistic intracellular cAMP level. Furthermore, our findings showed that CAFA-elevated cAMP phosphorylates VASP (Ser 157 ), an A-kinase substrate, to inhibit collagen-induced platelet aggregation. The inhibition of TXA2 production by CAFA contributed to COX-1 inhibition. Therefore, these results suggest that CAFA is an effective negative feedback regulator of platelet aggregation, a cause of thrombosis and atherosclerosis and a regulatory factor of the myocardial infarction. mobilization via the cAMP/A-kinase/IP3R phosphorylation pathway by elevating cAMP production but not cGMP production. Furthermore, because CAPE is known to elevate cGMP only, and not cAMP 24) , this is apparent evidence that CAFA has a different inhibitory mode of action from CAPE in platelet aggregation. CAFA-inhibited [Ca 2＋ ]i mobilization (Fig. 5A) was increased by the A-kinase inhibitor Rp-8-BrcAMPS, but not the G-kinase inhibitor Rp-8-BrcGMPS, in a dose-dependent manner (Fig. 5B) , and CAFA-elevated IP3R phosphorylation was inhibited by the A-kinase inhibitor Rp-8-Br-cAMPS, but not the G-kinase inhibitor Rp-8-Br-cGMPS (Fig. 6) .
Accordingly, these results suggest that the inhibition of [Ca 2＋ ]i mobilization by CAFA (Fig. 5A) potently is resulted from cAMP/A-kinase-dependent IP3R phosphorylation rather than cGMP/G-kinasedependent IP3R phosphorylation. Otherwise, CAFAreduced [Ca 2＋ ]i would not be increased and CAFAelevated IP3R phosphorylation would not be decreased by the A-kinase inhibitor Rp-8-Br-cAMPS. Therefore, it is thought that CAFA has a different mode of action from CAPE, an analogue of CAFA, having a cGMPdependent antiplatelet function. Another downstream pathway of both cAMP/A-kinase and cGMP/G-kinase also involve in phosphorylating VASP to inhibit platelet aggregation. Ser 157 at 50kDa of VASP is phosphorylated by the cAMP/A-kinase pathway, whereas Ser 239 at 50kDa of VASP is phosphorylated by the cGMP/ G-kinase pathway 42, 43) . Therefore, the phosphorylation of Ser 157 or Ser 239 at 50kDa of VASP is a useful indicator for monitoring the cAMP/A-kinase and cGMP/G-kinase pathways. CAFA strongly caused the cAMP-dependent phosphorylation of VASP (Ser 157 )-50kDa (Fig. 7A) .
This suggests that CAFA-elevated cAMP (Fig. 4A ) strongly phosphorylates VASP (Ser 157 )-50kDa via A-kinase activation. In contrast, CAFA did not cause the cGMP-dependent phosphorylation of VASP (Ser 239 )-50kDa (Fig. 7B) . This suggests that CAFAelevated cGMP (Fig. 4B) did not involve in the phosphorylation of VASP (Ser 239 )-50kDa. Eigenthaler et al. 44) reported that a small elevation in cAMP is enough to activate most A-kinases, whereas even a several fold elevation of the cGMP level may stimulate only a small fraction of total G-kinases. This previous report 44) indicates that even a little cAMP is enough to phosphorylate VASP (Ser 157 ), an A-kinase substrate, while a large amount of cGMP is required to phosphorylate VASP (Ser 239 ), a G-kinase substrate. Accordingly, even though CAFA (50 μM) increased the cGMP level to 2.1±0.05 pmoL/10 8 platelets compared with that (1.1±0.01 pmoL/10 8 plate-
